RCT (n=301)
open-label
null
Yes
Review highlights significant findings in infectious diseases, indicating vital insights for healthcare professionals.
The world of infectious diseases, for various reasons, before and after the COVID-19 pandemic, capture the attention of the scientific community, either due to the epidemiological data of various microbial agents that are emerging, due to the implementation with successful results of new diagnostic strategies or due to the appearance of new therapeutic options, which encourage healthcare workers to continue on the front line. Topics such as antimicrobial resistance, S. aureus bacteremia, clostridioides difficile, short treatments for tuberculosis, prosthetic joint infection or invasive fungal infections are included. In this article, we want to highlight, among many others, seven recently published articles that deserve our attention, full of useful information to keep us updated.
No takes yet. Share an insight, caveat, or question.
Algara et al. (2023) conducted an RCT in rifampicin-resistant pulmonary tuberculosis (n=301). Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin (BPaLM) vs. 9-to-20-month standard-care regimen was evaluated on Unfavorable status at 72 weeks after randomization (null, 95% CI null, p=null).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: